Commenting on the financial results, Axel Sven Malkomes, CFO, said: “Our decisive actions in 2024 to enhance fiscal discipline have significantly strengthened our financial foundation, securing a robust cash position that supports our runway into 2028. This financial strength provides CureVac (CVAC) with the flexibility and resources needed to accelerate innovation in our mRNA pipeline.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVAC:
- CureVac Receives FDA Clearance for Phase 1 Trial of mRNA Immunotherapy
- CureVac receives IND clearance to initiate Phase 1 trial for CVHNLC
- Biotech Alert: Searches spiking for these stocks today
- Lululemon reports Q4 beat, CoreWeave IPO priced at $40: Morning Buzz
- Morning Movers: U.S. Steel climbs following report of renewed Nippon talks
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue